Suppr超能文献

药物与 Sudlow 位点 I 的结合会损害人血清血红素白蛋白催化过氧亚硝酸盐解毒的变构作用。

Drug binding to Sudlow's site I impairs allosterically human serum heme-albumin-catalyzed peroxynitrite detoxification.

机构信息

Department of Biology and Interdepartmental Laboratory for Electron Microscopy, University Roma Tre, Roma, Italy.

出版信息

IUBMB Life. 2010 Oct;62(10):776-80. doi: 10.1002/iub.381.

Abstract

Heme endows human serum albumin (HSA) with globin-like reactivity and spectroscopic properties. Here, the effect of chlorpropamide, digitoxin, furosemide, indomethacin, phenylbutazone, sulfisoxazole, tolbutamide, and warfarin on peroxynitrite isomerization to NO(3) (-) by ferric HSA-heme (HSA-heme-Fe(III)) is reported. Drugs binding to Sudlow's site I impair dose-dependently peroxynitrite isomerization by HSA-heme-Fe(III). The allosteric modulation of HSA-heme-Fe(III)-mediated peroxynitrite isomerization by drugs has been ascribed to the pivotal role of Tyr150, a residue that either provides a polar environment in Sudlow's site I or protrudes into the heme cleft (i.e., the fatty acid site 1, FA1), depending on ligand occupancy of either sites.

摘要

血红素赋予人血清白蛋白(HSA)球蛋白样反应性和光谱特性。在这里,报告了氯丙嗪、地高辛、呋塞米、吲哚美辛、保泰松、磺胺异恶唑、甲苯磺丁脲和华法林对铁 HSA-血红素(HSA-血红素-Fe(III))催化过氧亚硝酸盐异构化为 NO(3) (-)的影响。结合到 Sudlow 位点 I 的药物会剂量依赖性地抑制 HSA-血红素-Fe(III)催化的过氧亚硝酸盐异构化。药物对 HSA-血红素-Fe(III)介导的过氧亚硝酸盐异构化的变构调节归因于 Tyr150 的关键作用,该残基要么在 Sudlow 位点 I 提供极性环境,要么突入血红素裂隙(即脂肪酸位点 1,FA1),具体取决于任一部位的配体占据情况。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验